Health economics

This course offers a practical overview of market access and its application in business development and clinical strategy decisions. You’ll gain essential knowledge of payer expectations and HTA systems in Europe, and learn how access-related data should inform strategic decision-making. Through real-world examples and interactive group work, you’ll be equipped to make access-aware decisions in business development and clinical strategy

Real World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs) to further reduce regulatory, payer, physician and patient uncertainty. Unfortunately, many companies struggle implementing it. The key ingredient to success is a cross-functional organisation where managers have widespread knowledge of the fundamentals and a shared vocabulary. In this course you will learn the fundamentals of RWE so that you can contribute effectively when decisions are made and/or when implementing RWE studies.

Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.

Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.